Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Mini Oral session - Haematological malignancies

267O - Treatment outcome for gastric mucosa-associated lymphoid tissue lymphoma with Helicobacter Pylori negative

Date

24 Nov 2019

Session

Mini Oral session - Haematological malignancies

Presenters

Sung-Nam Lim

Citation

Annals of Oncology (2019) 30 (suppl_9): ix91-ix96. 10.1093/annonc/mdz427

Authors

S. Lim1, B.S. Sohn2

Author affiliations

  • 1 Internal Medicine/hemato-oncology, Inje University Haeundae Paik Hospital, 612-896 - Busan/KR
  • 2 Internal Medicine, Sanggye Paik Hospital, Seoul/KR

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 267O

Background

Unlike that for Helicobacter pylori (H.pylori)-positive gastric mucosa-associated lymphoid tissue (MALT) lymphoma, the management strategy for H.pylori-negative MALT lymphoma remains controversial. Therefore, the aim of the present study was to examine the success of each treatment option for H.pylori-negative gastric MALT lymphomas.

Methods

Between June 2000 and June 2017, a total of 89 H.pylori-negative gastric MALT lymphoma patients were enrolled retrospectively. H.pylori-positive status was defined by positive results for the biopsy urease test and histology. They had all been diagnosed by endoscopy and had a complete staging including CT-scan. Tumors that had resolved to complete remission score of GELA histologic grading system were considered treatment-responsive.

Results

Sixty-two patients (69.7%) underwent H.pylori eradication therapy. After H.pylori eradication, ChR was achieved in 15 patients (24.2%) and pMRD in 13 (21.0%). he median time from H.pylori eradication to ChR or pMRD was 84 days. Fifteen patients took radiotherapy and six patients chose combination chemotherapy with or without rituximab as following, RCVP in 3, CVP in 1, and CHOP in 2. The all of them who took radiotherapy and chemotherapy achieved ChR. Median follow-up period was 45.4 months, lymphoma relapse was observed in nine patients (10.1%). Disease progression was observed in 3 of 33 non-responders. Probabilities of overall survival and event-free survival at 10 years were 98.5%, and 61.4%, respectively.

Conclusions

A substantial proportion of patient with H.pylori-negative gastric MALT lymphoma remain antibiotic-responsive and can be cured using radiotherapy and chemotherapy.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.